Skip to main content

Table 1 Published data from studies of GH treatment in Noonan patients

From: Five-year response to growth hormone in children with Noonan syndrome and growth hormone deficiency

Reference No. patients (M/F) Height SDS at start of GH treatment# GH dose (mg/kg/week) Duration of GH treatment (yrs) Height SDS at last observation#
Ahmed et al. 1991 [25] 6 (3/3) From −3.5 to −2.3 0.18 1 -
Thomas et al. 1993 [31] 5 (4/1) From −4.2 to −2.2 0.35 2.9 From −3.3 to −1.6
Municchi et al. 1995 [32] 4 (0/1) From −1.9 to 0.2* 0.17 3 From −0.9 to 0.9*
Cotterill et al. 1996 [33] 30 (19/11) −3.01 ± 0.1 0.33 1 −2.36 ± 0.1
de Schepper et al. 1997 [15] 23 (18/5) −2.28 ± 0.68 0.35 1 −1.78 ± 0.76
Soliman et al. 1998 [34] 12 (3/9) −2.2 ± 0.6 0.28 1 1.45 ± 0.3
MacFarlane et al. 2001 [35] 23 (16/7) −2.7 ± 0.4 0.33 3 −1.9 ± 0.9
Ogawa et al. 2004 [36] 15 (8/6) −2.8 ± 0.7 0.17 2 −2.2 ± 0.5
Ferreira et al. 2005 [22] 14 (10/4) −3.5 ± 1.0 (PTPN11 mutation) 0.29 3 0.76 ± 0.41 (PTPN11 mutation)
−3.4 ± 1.0 (no PTPN11 mutation) 1.74 ± 0.10 (no PTPN11 mutation)
Binder et al. 2005 [37] 29 (19/10) −3.5 ± 1.0 (PTPN11 mutation) 0.30 1 0.66 ± 0.21 (PTPN11 mutation)$
−3.4 ± 1.0 (no PTPN11 mutation) 1.26 ± 0.36 (no PTPN11 mutation)$
Osio et al. 2005 [38] 25 (12/13) −2.9 ± 0.4 0.23-0.46 1-9 −1.2 ± 1.0
Limal et al. 2006 [23] 35 (19/16) −3.1 ± 0.9 (PTPN11 mutation) 0.30-0.46 2 −3.1 ± 1.4 (PTPN11 mutation)
−2.4 ± 0.8 (no PTPN11 mutation) −2.0 ± 0.9 (no PTPN11 mutation)
Noordam et al. 2008 [21] 29 (21/8) From −4.1 to −1.8 0.35 3-10.3 From −3.0 to −0.3
Choi et al. 2012 [24] 28 (14/4) −2.8 ± 0.9 0.46 1 −2.0 ± 0.9
  1. #Mean ± standard deviation or range
  2. *Noonan reference [39]
  3. $Change in height SDS